Get the Stockscreener App
85.34
1.56%
1.31
After Hours:
85.21
-0.13
-0.15%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk Adr stock is traded at $85.34, with a volume of 5.44M.
It is up +1.56% in the last 24 hours and down -0.45% over the past month.
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
See More
Previous Close:
$84.03
Open:
$84.6
24h Volume:
5.44M
Relative Volume:
0.71
Market Cap:
$379.90B
Revenue:
$39.36B
Net Income/Loss:
$13.79B
P/E Ratio:
27.65
EPS:
3.086
Net Cash Flow:
$9.83B
1W Performance:
+5.23%
1M Performance:
-0.45%
6M Performance:
-33.96%
1Y Performance:
-21.72%
1-Day Range:
$83.94
$86.47
1-Week Range:
$83.90
$89.97
52-Week Range:
$78.17
$148.15
Novo Nordisk Adr Stock (NVO) Company Profile
Name
Novo Nordisk Adr
Sector
Industry
Phone
-
Address
-
Compare NVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
85.34 | 379.90B | 39.36B | 13.79B | 9.83B | 3.086 |
|
LLY
Lilly Eli Co
|
823.23 | 778.66B | 40.86B | 8.37B | -2.28B | 9.25 |
|
JNJ
Johnson Johnson
|
152.87 | 344.63B | 88.82B | 14.07B | 19.03B | 5.79 |
|
ABBV
Abbvie Inc
|
175.59 | 310.55B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
98.92 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-25 | Upgrade | Bernstein | Underperform → Mkt Perform |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Neutral |
| Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-02-23 | Initiated | Argus | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-28-22 | Downgrade | UBS | Neutral → Sell |
| Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
| Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
| Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-25-22 | Downgrade | Liberum | Hold → Sell |
| Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
| May-11-20 | Downgrade | UBS | Buy → Neutral |
| May-04-20 | Initiated | Cowen | Market Perform |
| Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
| Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk Adr Stock (NVO) Latest News
NOVO NORDISK ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading Weight Loss in Small Trial - Morningstar
2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs - Morningstar
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Is Now The Time To Buy PDD Holdings Inc ADR (NASDAQ: PDD) Stock? - Stocks Register
Where Do Analysts Think The Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Is Going - Stocks Register
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Precidian Investments Builds Out Its ADRhedged ETF Lineup with Four New Strategies, Offering Targeted International Exposure with Integrated Currency Hedge - Business Wire
Eli Lilly, Novo Nordisk Went Head-to-Head on Weight-Loss Drugs in 2024. There’s a Clear Winner. - Barron's
Is Alibaba Group Holding Ltd ADR’s (NYSE:BABA) Stock On The Decline? - Stocks Register
European Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday Trading - MSN
Will Novo Nordisk (NVO) Stock Recover To $145 Levels? - Forbes
Weekly Upgrades and Downgrades - InvestorPlace
NVO Stock Plunges As Obesity Drug CagriSema Misses Target In Phase III - Barchart
Novo Nordisk Stock Crashes More Than 20% After Disappointing Obesity Drug Data. Eli Lilly Shares Soar. - Barron's
Markets News, December 20, 2024: Stocks Rise After Encouraging Inflation Data to Wrap Up Rough Week; Major Indexes Post Weekly Losses - Investopedia
Novo Nordisk: Shares Look Fairly Valued After CagriSema Disappointment - Morningstar
European Equities Traded in the US as American Depositary Fall in Wednesday Trading - MSN
Novo Nordisk A/S - GlobeNewswire Inc.
Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue - Barron's
Novo Nordisk Adr Stock (NVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):